Trial reportAlzheimer's & dementia : the journal of the Alzheimer's Association2026
Altered locus coeruleus links to atrophy and hypometabolism in individuals with high Alzheimer's disease biomarkers.
Trial report in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02977819 (Interventional Study in Cognitively Intact Seniors Aiming to Assess the Effects of Meditation Training and Foreign Language Learning on Behavioral, Biological and Neuroimaging Measures), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Interventional Study in Cognitively Intact Seniors Aiming to Assess the Effects of Meditation Training and Foreign Language Learning on Behavioral, Biological and Neuroimaging Measures
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionThe locus coeruleus (LC), the first region to contain tau pathology in Alzheimer's disease (AD), releases norepinephrine, which has a neuroprotective role. We examined whether LC integrity relates to whole-brain integrity and how AD biomarkers may moderate this relationship.
methodsLC intensity and volume were estimated using automatic segmentation on neuromelanin-sensitive magnetic resonance imaging acquired in n = 71 cognitively unimpaired elderly from the Age-Well randomized controlled trial. We investigated the associations between LC integrity and whole-brain gray matter volume (GMV) and glucose metabolism, as well as the interactions with amyloid positron emission tomography and plasma phosphorylated tau231, neurofilament light chain and glial fibrillary acidic protein.
resultsWhile only LC intensity was directly associated with GMV, both LC measures (intensity and volume) interacted positively with AD biomarkers to predict GMV and glucose metabolism. DISCUSSION: Our results support concomitant LC and gray matter alterations in the context of aging and elevated AD biomarker levels. CLINICAL
trial registrationAge-Well randomized clinical trial of the Medit-Ageing European Project. TRIAL REGISTRATION NUMBER: EudraCT:2016-002,441-36; IDRCB:2016-A01767-44; ClinicalTrials.gov Identifier: NCT02977819.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.